1-6 of 6
Andras Rosta
Close
Sort by
Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli
Journal: Blood
Blood (2018) 132 (Supplement 1): 783.
https://doi.org/10.1182/blood-2018-99-116845
Published: 2018
Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Sally F Barrington, Judith Trotman, Deniz Sahin, David Belada, Andrew Davies, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Wolfgang Hiddemann, Robert Marcus, Tina Nielsen, Federico Mattiello, Harald Zeuner, Michel Meignan
Journal: Blood
Blood (2018) 132 (Supplement 1): 2882.
https://doi.org/10.1182/blood-2018-99-117235
Published: 2018
Journal Articles

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

Joseph M Connors, MD, Wojciech Jurczak, PhDMD, David J. Straus, MD, Stephen M Ansell, MD PhD, Won Seog Kim, MD, Ph. D., Andrea Gallamini, MD, Anas Younes, MD, Sergei Alekseev, PhD, Arpad Illes, MD, Marco Picardi, Ewa Lech-Maranda, MDPhD, Yasuhiro Oki, MD, Tatyana A Feldman, MD, Piotr Smolewski, MD PhD, Kerry J Savage, BSc, MD MSc, Nancy L. Bartlett, MD, Jan Walewski, MD PhD, Robert W. Chen, MD, Rod Ramchandren, MD, Pier Luigi Zinzani, MD, David Cunningham, MD FRCP, Dae Seog Heo, MD, Andras Rosta, MD, Neil Josephson, MD, Katherine L. Ruffner, MD, Jessica Sachs, Rachael Liu, PhD, Hina Jolin, Pharm D, Dirk Huebner, MD, John A. Radford, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 6.
https://doi.org/10.1182/blood.V130.Suppl_1.6.6
Published: 2017
Journal Articles

Immunochemotherapy As Induction (R-CHOP and R-HyperC-VAD/R-MA) in Mantle Cell Lymphoma, a Hungarian Multicenter Open Label Phase II Study (Rituximab [MabThera®] in Mantle Cell Lymphoma, REMENY)

Miklos Udvardy, MD, PhD, Andras Rosta, MD, PhD, Zoltan Gasztonyi, MD, Zita Borbenyi, MD, PhD, Gaspar Radvanyi, MD, Miklos Egyed, MD, PhD, Beata Gasztonyi, MD, PhD, Hajna Losonczy, MD, PhD, Andras Matolcsy, MD, PhD, Agnes H. Andrasfalvy, MD, Tamas J. Schneider, MD
Journal: Blood
Blood (2012) 120 (21): 4889.
https://doi.org/10.1182/blood.V120.21.4889.4889
Published: 2012
Journal Articles

Results of the Interim Analysis of the “HUSOM” Trial: Hungarian Study of Maintenance After Rituximab Pretreatment, A Multicentre, Phase III, Open-Label Study Evaluating the Benefit of a Long-Term MabThera (rituximab) Maintenance Therapy in Patients with Advance Follicular Lymphoma After Induction of Response (CR(u) or PR) with a MabThera (rituximab)-Containing First Line Regimen

Tamas J. Schneider, MD, Andras Rosta, MD, PhD, Hajna Losonczy, MD, PhD, Gaspar Radvanyi, MD, Gyorgy Ujj, MD, Arpad Illes, MD, PhD, János Jakucs, MD, Zita Borbenyi, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2714.
https://doi.org/10.1182/blood.V118.21.2714.2714
Published: 2011
Journal Articles

Excellent Results In the Treatment of Primary Mediastinal Lymphomas

Tamas Schneider, Zsuzsanna Molnar, Erika Toth, Jozsef Lovey, Erika Szaleczky, Erika Varady, Beata Deak, Fatima Varga, Sandor Fekete, MD, Andras Rosta
Journal: Blood
Blood (2010) 116 (21): 4915.
https://doi.org/10.1182/blood.V116.21.4915.4915
Published: 2010